Peptris Technologies is a technology company.
Peptris Technologies has raised $1.0M across 1 funding round.
Peptris Technologies has raised $1.0M in total across 1 funding round.
Peptris Technologies has raised $1.0M in total across 1 funding round.
Peptris Technologies's investors include Speciale Invest.
Peptris Technologies is an AI-powered preclinical drug discovery company that develops novel therapeutics primarily for oncology, inflammation, and rare diseases. It leverages a proprietary computational platform integrating artificial intelligence (AI), machine learning (ML), and generative AI to design and optimize drug candidates, significantly reducing the need for costly and time-consuming wet lab testing. The platform generates novel chemical entities, repurposes approved drugs, and rescues clinically safe molecules for new indications. Peptris serves pharmaceutical and biotech companies, as well as rare disease organizations, aiming to accelerate drug discovery and improve efficiency in the pharmaceutical R&D process[1][2][3].
Founded in 2019 and based in Bengaluru, India, Peptris was established by a team with expertise in AI, computational biology, and drug discovery. The idea emerged from the need to address the inefficiencies and high costs in traditional drug development by applying advanced AI models, including large language models and neural networks, to understand chemical space and predict drug-like properties. Early traction includes developing a pipeline of preclinical assets validated in vitro and in vivo, and entering licensing agreements such as the one with Revio Therapeutics for a Duchenne Muscular Dystrophy asset, demonstrating the platform’s potential to impact rare disease therapeutics[1][2][3][4].
Peptris rides the growing trend of integrating AI and machine learning into pharmaceutical R&D to combat rising costs and declining efficiency in drug discovery. The timing is critical as the pharmaceutical industry faces pressure to innovate faster and more cost-effectively, especially for complex diseases and rare conditions with unmet medical needs. By combining advances in natural language processing, image processing, and deep learning, Peptris contributes to a paradigm shift where computational methods accelerate early-stage drug development. Its platform supports the broader ecosystem by enabling biotech startups and pharma companies to access AI-driven insights and novel candidates, potentially transforming how new medicines are discovered and developed globally[1][3][5].
Peptris is poised to expand its footprint in global biotech markets through licensing deals and partnerships, leveraging its AI platform to address challenging diseases like Duchenne Muscular Dystrophy. Future trends shaping its journey include continued advances in AI model architectures, increased adoption of computational drug discovery, and growing demand for therapies in rare and complex diseases. As Peptris matures, it may evolve from a preclinical discovery engine to a key player influencing drug pipelines worldwide, potentially integrating more deeply with clinical development and personalized medicine initiatives. Its success will depend on scaling partnerships, validating more assets, and maintaining technological leadership in AI-driven drug design[1][2][3].
Peptris Technologies has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $1.0M Seed | Speciale Invest |